Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria during screening and prior to the first dose of study medication being administered on D0 (criteria 1 or 2 and all 3, 4 and 5):~1. Patients (male or female) presenting with a ruptured abdominal aortic aneurysm (RAAA) diagnosed by ultrasound or CT-scan in the emergency room~   * all forms of infrarenal RAAAs with or without coexisting iliac aneurysms are included or~2. Patients (male or female) presenting with symptoms of RAAA known to have an infrarenal AAA and proceeding straight to open repair without radiological assessment and confirmed rupture (=retroperitoneal haematoma) in operation~   and~3. Aneurysma repair must be infra-renal, i.e. the proximal anastomosis must be below the renal arteries and the renal arteries have to stay intact. Temporary above the renal clamping can be used for a maximum of 30 minutes (total clamping time)~   and~4. Patients providing informed consent~   and~5. Age of 18 years or higher~Exclusion Criteria:~To be eligible for inclusion into this study, each patient must not meet any of the following exclusion criteria during screening or prior to the first dose of study medication being administered:~1. Moribund patient not eligible for treatment in ICU or expected to survive surgery~2. Markedly short life expectancy, e.g. advanced malignant disease~3. Current participation in another experimental treatment protocol~4. Significant congestive heart failure, defined as New York Heart Association (NYHA) class IV~5. Current treatment with Interferon (IFN) alpha or IFN beta~6. Dialysis therapy for chronic renal failure~7. Irreversible shock from haemorrhage~8. Unconsciousness or inability to give consent~9. Ruptured Endovascular Aortic Repair (rEVAR) first (prior attempt for endovascular aortic repair for the current rupture)~10. Diagnosed cirrhosis~11. Pregnancy and women with child bearing potential without negative pregnancy test~12. Rupture not confirmed by CT or intra-operatively (impending ruptures are excluded)~13. RAAA requiring repair of the renal arteries or the proximal aorta~    * thoracoabdominal aneurysms requiring immediate repair~   * damaged renal arteries during emergency clamping requiring repair~Note:~* temporary clamping above the renal arteries (max 30 min total clamping time above the renal arteries) does not lead to exclusion~* ligation of the left renal vein does not lead to exclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FP-1201-lyo 10 µg (Type: EXPERIMENTAL): FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
- FP-1201-lyo Placebo (Type: PLACEBO_COMPARATOR): FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection

Based on this trial design, predict the completion outcome and termination type (if applicable).